RFA-HD-13-002 requires the inclusion of a Clinical Translational Core within each IDDRC, addressing a combination of activities that includes: (a) recruitment of research participants, (b) subject assessment, phenotyping, or treatment, (c) development of biomarkers, (d) manufacturing services, (e) highthroughput screening, and/or (f) collection of samples from individuals with IDD for biobanking. As described in our Introductory Overview and the following Core descriptions, many of these activities are supported by other Cores and existing resources within the large and multidisciplinary research environment developed within our Institutions over the years. Therefore, the overall objective of the Clinical Translational Core is to complement those resources and coordinate access for IDDRC-supported investigators. This will contribute to our primary goal of enhancing the conversion of basic science discoveries into effective, commercially available disease-altering therapies for children and adults with genetic and acquired intellectual and developmental disabilities. The Core will be structured to complement our Clinical Trials Unit (CTU), a program established three years ago in response to the increasing emphasis on translational research within our IDDRC and the broader research program it supports. The CTU is focused on the development of treatments targeting developmental disorders, including conducting investigational dmg trials at all phases. The Clinical Translational Core will expand upon CTU capabilities to provide expert resources including consultation on biostatistics and protocol design, pre-review prior to submission of protocols to the institutional review board (IRB) and hands-on advice and help with carrying out investigational protocols by experienced clinical trials faculty, research coordinators and administrative staff.
| Oeltzschner, Georg; Chan, Kimberly L; Saleh, Muhammad G et al. (2018) Hadamard editing of glutathione and macromolecule-suppressed GABA. NMR Biomed 31: |
| Patros, Connor H G; L Sweeney, Kristie; Mahone, E Mark et al. (2018) Greater delay discounting among girls, but not boys, with ADHD correlates with cognitive control. Child Neuropsychol 24:1026-1046 |
| Pillai, Ajay S; McAuliffe, Danielle; Lakshmanan, Balaji M et al. (2018) Altered task-related modulation of long-range connectivity in children with autism. Autism Res 11:245-257 |
| Jacobson, Lisa A; Schneider, Heather; Mahone, E Mark (2018) Preschool Inhibitory Control Predicts ADHD Group Status and Inhibitory Weakness in School. Arch Clin Neuropsychol 33:1006-1014 |
| Stephens, Jaclyn A; Denckla, Martha B; McCambridge, Teri et al. (2018) Preliminary use of the PANESS for detecting subtle motor signs in adolescents with sport-related concussion: a brief report. Am J Phys Med Rehabil : |
| Mikkelsen, Mark; Loo, Rachelle S; Puts, Nicolaas A J et al. (2018) Designing GABA-edited magnetic resonance spectroscopy studies: Considerations of scan duration, signal-to-noise ratio and sample size. J Neurosci Methods 303:86-94 |
| Rosch, Keri S; Crocetti, Deana; Hirabayashi, Kathryn et al. (2018) Reduced subcortical volumes among preschool-age girls and boys with ADHD. Psychiatry Res Neuroimaging 271:67-74 |
| Slomine, Beth S; Silverstein, Faye S; Christensen, James R et al. (2018) Neurobehavioural outcomes in children after In-Hospital cardiac arrest. Resuscitation 124:80-89 |
| Pilarowski, Genay O; Vernon, Hilary J; Applegate, Carolyn D et al. (2018) Missense variants in the chromatin remodeler CHD1 are associated with neurodevelopmental disability. J Med Genet 55:561-566 |
| Kim, Sangjune; Yun, Seung Pil; Lee, Saebom et al. (2018) GBA1 deficiency negatively affects physiological ?-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 115:798-803 |
Showing the most recent 10 out of 198 publications
